Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.
OBJECTIVE
Drug administration modifies the balance of neurotransmitter-controlled ion channel activity and consequently the firing pattern of local neuronal populations and intracerebral field potentials. Fast Fourier Transformation of these field potentials provides an electropharmacogram depicting drug-induced changes within defined frequency ranges. The present investigation was undertaken to investigate the difference between atypical and typical antipsychotic drugs.


METHODS
Adult Fisher rats were implanted with 4 bipolar concentric steel electrodes using a stereotactic surgical procedure. Field potentials from four selected brain areas in freely moving rats were used to analyse the frequency content of the electropharmacogram after administration of 4 clinically used atypical antipsychotic drugs.


RESULTS
Atypical antipsychotics exerted effects similar to those reported for typical antipsychotics, on the electropharmacogram during the first hour after administration, whereas clear differences emerged during the second and third hour after dosing. During the latter period, only atypical antipsychotic drugs produced a statistically significant decrease in alpha1 and beta1 spectral power, especially within the striatum, somewhat less in the cortex.


CONCLUSIONS
Previous studies have attributed alpha1 frequency changes to the influence of 5-hydroxytryptamine (5-HT) and the present data are consistent with additional binding of atypical drugs to 5-HT receptors. This implies that a change in the balance between dopaminergic and 5-hydroxytryptaminergic neurotransmission (activation of both) is likely to underlie the relative lack of extrapyramidal side effects characteristic of atypical antipsychotics and also for their higher efficacy in the treatment of mood and cognition deficits in schizophrenics.
Dimpfel
W
W
Justus-Liebig-University Giessen, Hessen, Germany. w.dimpfel@neurocode-ag.com
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology; D003024:Clozapine / Q000008:administration & dosage / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000502:physiology; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects* / Q000379:methods; D005260:Female; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D007274:Injections, Intraperitoneal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009068:Movement; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology; D000069348:Quetiapine Fumarate; D051381:Rats; D011916:Rats, Inbred F344; D012154:Reticular Formation / Q000187:drug effects / Q000502:physiology; D018967:Risperidone / Q000008:administration & dosage / Q000494:pharmacology; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine
Eur Neuropsychopharmacol. 1994 Dec;4(4):491-501
7894260
Int Clin Psychopharmacol. 1994 Spring;9(1):17-24
7910833
Br J Clin Pharmacol. 1999 Sep;48(3):323-30
10510142
Eur Neuropsychopharmacol. 2005 Dec;15(6):673-82
16009538
J Coll Physicians Surg Pak. 2006 Aug;16(8):556-62
16899192
Schizophr Res. 2006 Dec;88(1-3):265-74
16916599
Psychopharmacology (Berl). 2007 May;191(4):995-1004
17333135
Neuropsychopharmacology. 2007 Aug;32(8):1715-26
17251913
J Pharmacol Exp Ther. 1989 Oct;251(1):238-46
2571717
J Psychiatry Neurosci. 2000 Mar;25(2):161-6
10740989
Neuropsychopharmacology. 2000 Jun;22(6):642-9
10788763
Psychopharmacology (Berl). 2001 Nov;158(3):281-8
11713618
CNS Drugs. 2002;16(1):23-45
11772117
Drugs. 2002;62(8):1217-51
12010089
Br J Psychiatry. 2002 Oct;181:271-5
12356650
Methods Find Exp Clin Pharmacol. 2002;24 Suppl C:85-9
12575491
Eur J Med Res. 2003 May 30;8(5):199-207
12844474
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1145-58
14642973
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72
14642974
Nature. 1976 Jun 24;261(5562):717-9
945467
Neuropsychobiology. 1986;16(2-3):163-8
3587575
Neuropsychobiology. 1987;18(4):212-8
2841622
Psychopharmacology (Berl). 1989;98(3):297-303
2568652
Psychopharmacology (Berl). 1992;107(2-3):195-202
1352051
Psychopharmacology (Berl). 1999 Jun;144(3):272-8
10435394